ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR

|   Science & Medicine

  • ImCheck Therapeutics today announced that it will present data from its Phase I/IIa clinical trial EVICTION-2 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.

The EVICTION-2 trial is evaluating the combination of ImCheck’s lead program, ICT01, a γ9δ2 T cell-activating monoclonal antibody targeting BTN3A, combined with low dose IL-2, to selectively expand the number of γ9δ2 T cells in relapsed/refractory patients with solid tumors. The conference will be held in Orlando, Florida, from April 14 to 19, 2023, and clinical trial abstracts will be posted online on April 14.

Details of the poster presentation are:

  • Abstract title: “First-in-Human Study of ICT01, an Anti-BTN3A Activating Monoclonal Antibody  in Combination with Low Dose IL-2 in Patients with Advanced Solid Tumors (EVICTION-2 Study)”
  • Session title: First-in-Human Phase I Clinical Trials 2
  • Abstract number: CT179
  • Authors: Johann de Bono, Stéphane Champiat, Francois-Xavier Danlos, Martin Wermke, Volker Kunzmann, Aude De Gassart, Emmanuel Valentin, Marina Iché, Maelle Mairesse, Patrick Brune, Katrien Lemmens, Aurélien Marabelle, Daniel Olive, Paul Frohna
  • Date/Time: Tuesday Apr 18, 2023 9:00 AM - 12:30 PM Eastern Time
  • Location: Poster Section 45
  • Poster Board Number: 11